286 related articles for article (PubMed ID: 31325705)
1. Synergistic combination therapy of lung cancer: Cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-Demethylnobiletin.
Guo S; Zhang Y; Wu Z; Zhang L; He D; Li X; Wang Z
Biomed Pharmacother; 2019 Oct; 118():109225. PubMed ID: 31325705
[TBL] [Abstract][Full Text] [Related]
2. Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer.
Liang Y; Tian B; Zhang J; Li K; Wang L; Han J; Wu Z
Int J Nanomedicine; 2017; 12():1699-1715. PubMed ID: 28280336
[TBL] [Abstract][Full Text] [Related]
3. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
[TBL] [Abstract][Full Text] [Related]
4. A Gastric Cancer Peptide GX1-Modified Nano-Lipid Carriers Encapsulating Paclitaxel: Design and Evaluation of Anti-Tumor Activity.
Jian Y; Zhao M; Cao J; Fan T; Bu W; Yang Y; Li W; Zhang W; Qiao Y; Wang J; Wen A
Drug Des Devel Ther; 2020; 14():2355-2370. PubMed ID: 32606603
[TBL] [Abstract][Full Text] [Related]
5. Lung cancer combination therapy: doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers.
Cao C; Wang Q; Liu Y
Drug Des Devel Ther; 2019; 13():1087-1098. PubMed ID: 31118562
[No Abstract] [Full Text] [Related]
6. Synergistic Anticancer Effect of a Combination of Paclitaxel and 5-Demethylnobiletin Against Lung Cancer Cell Line In Vitro and In Vivo.
Tan KT; Li S; Li YR; Cheng SL; Lin SH; Tung YT
Appl Biochem Biotechnol; 2019 Apr; 187(4):1328-1343. PubMed ID: 30229430
[TBL] [Abstract][Full Text] [Related]
7. Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Box-Behnken design.
Emami J; Rezazadeh M; Sadeghi H; Khadivar K
Pharm Dev Technol; 2017 May; 22(3):370-382. PubMed ID: 27689412
[TBL] [Abstract][Full Text] [Related]
8. Nanocarrier-Based Combination Chemotherapy for Resistant Tumor: Development, Characterization, and Ex Vivo Cytotoxicity Assessment.
Raikwar S; Vyas S; Sharma R; Mody N; Dubey S; Vyas SP
AAPS PharmSciTech; 2018 Nov; 19(8):3839-3849. PubMed ID: 30280350
[TBL] [Abstract][Full Text] [Related]
9. Targeted Nanostructured Lipid Carriers for Delivery of Paclitaxel to Cancer Cells: Preparation, Characterization, and Cell Toxicity.
Rezazadeh M; Emami J; Hassanzadeh F; Sadeghi H; Rostami M; Mohammadkhani H
Curr Drug Deliv; 2017; 14(8):1189-1200. PubMed ID: 28472908
[TBL] [Abstract][Full Text] [Related]
10. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect.
Wang Y; Zhang H; Hao J; Li B; Li M; Xiuwen W
Drug Deliv; 2016 May; 23(4):1398-403. PubMed ID: 26079530
[TBL] [Abstract][Full Text] [Related]
11. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
12. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery.
Wu M; Fan Y; Lv S; Xiao B; Ye M; Zhu X
Drug Deliv; 2016 Oct; 23(8):2720-2725. PubMed ID: 26203691
[TBL] [Abstract][Full Text] [Related]
13. Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid-polymer hybrid nanoparticles.
Liu J; Cheng H; Han L; Qiang Z; Zhang X; Gao W; Zhao K; Song Y
Drug Des Devel Ther; 2018; 12():3199-3209. PubMed ID: 30288024
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin and paclitaxel co-delivered by folate-decorated lipid carriers for the treatment of head and neck cancer.
Yang J; Ju Z; Dong S
Drug Deliv; 2016 Nov; 24(1):792-799. PubMed ID: 28494629
[TBL] [Abstract][Full Text] [Related]
15. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.
Li Q; Lv S; Tang Z; Liu M; Zhang D; Yang Y; Chen X
Int J Pharm; 2014 Aug; 471(1-2):412-20. PubMed ID: 24905776
[TBL] [Abstract][Full Text] [Related]
16. Low density lipoprotein mimic nanoparticles composed of amphipathic hybrid peptides and lipids for tumor-targeted delivery of paclitaxel.
Qian J; Xu N; Zhou X; Shi K; Du Q; Yin X; Zhao Z
Int J Nanomedicine; 2019; 14():7431-7446. PubMed ID: 31686815
[TBL] [Abstract][Full Text] [Related]
17. PEGylated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: an efficient carrier with enhanced anti-tumour effects against lung cancer.
Zhang X; Gan Y; Gan L; Nie S; Pan W
J Pharm Pharmacol; 2008 Aug; 60(8):1077-87. PubMed ID: 18644200
[TBL] [Abstract][Full Text] [Related]
18. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
Qu J; Zhang L; Chen Z; Mao G; Gao Z; Lai X; Zhu X; Zhu J
Drug Deliv; 2016 Nov; 23(9):3408-3416. PubMed ID: 27181462
[TBL] [Abstract][Full Text] [Related]
19. Etoposide-loaded nanostructured lipid carriers for gastric cancer therapy.
Jiang H; Pei L; Liu N; Li J; Li Z; Zhang S
Drug Deliv; 2016 May; 23(4):1379-82. PubMed ID: 26162024
[TBL] [Abstract][Full Text] [Related]
20. Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells.
Zhou J; Sun M; Jin S; Fan L; Zhu W; Sui X; Cao L; Yang C; Han C
Drug Deliv; 2019 Dec; 26(1):281-289. PubMed ID: 30880491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
